Skip to Content

Generic Reyataz Availability

Reyataz is a brand name of atazanavir, approved by the FDA in the following formulation(s):

REYATAZ (atazanavir sulfate - capsule;oral)

REYATAZ (atazanavir sulfate - powder;oral)

Has a generic version of Reyataz been approved?

A generic version of Reyataz has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Reyataz and have been approved by the FDA:

atazanavir sulfate capsule;oral

  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: June 25, 2018
    Strength(s): EQ 150MG BASE [AB], EQ 200MG BASE [AB], EQ 300MG BASE [AB]
  • Manufacturer: CIPLA
    Approval date: August 9, 2018
    Strength(s): EQ 150MG BASE [AB], EQ 200MG BASE [AB], EQ 300MG BASE [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: September 24, 2018
    Strength(s): EQ 150MG BASE [AB], EQ 200MG BASE [AB], EQ 300MG BASE [AB]
  • Manufacturer: TEVA PHARMS USA
    Approval date: April 22, 2014
    Strength(s): EQ 150MG BASE [AB], EQ 200MG BASE [AB], EQ 300MG BASE [AB]

Note: No generic formulation of the following product is available.

  • atazanavir sulfate - powder;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Reyataz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Bisulfate salt of HIV protease inhibitor
    Patent 6,087,383
    Issued: July 11, 2000
    Inventor(s): Singh; Janak & Pudipeddi; Madhusudhan & Lindrud; Mark D.
    Assignee(s): Bristol-Myers Squibb Company

    The present invention provides the crystalline bisulfate salt of the formula ##STR1## which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.

    Patent expiration dates:

    • December 21, 2018
      Drug substance
      Drug product
    • June 21, 2019
      Pediatric exclusivity

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • September 24, 2018 - NEW PATIENT POPULATION
    • March 24, 2019 - PEDIATRIC EXCLUSIVITY

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.